Julie Green Sells 20,964 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 20,964 shares of Invivyd stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12. Following the transaction, the insider owned 107,717 shares in the company, valued at $170,192.86. This represents a 16.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Julie Green also recently made the following trade(s):

• On Tuesday, February 17th, Julie Green sold 19,663 shares of Invivyd stock. The stock was sold at an average price of $1.54, for a total value of $30,281.02.

Invivyd Trading Up 6.5%

NASDAQ IVVD traded up $0.10 on Wednesday, hitting $1.65. 1,468,415 shares of the company traded hands, compared to its average volume of 3,015,442. The business’s 50 day moving average price is $2.19 and its 200-day moving average price is $1.75. Invivyd, Inc. has a 52-week low of $0.46 and a 52-week high of $3.07. The company has a market capitalization of $384.65 million, a price-to-earnings ratio of -3.51 and a beta of 0.60.

Institutional Trading of Invivyd

Large investors have recently made changes to their positions in the business. Invesco Ltd. lifted its stake in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after buying an additional 391,617 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares during the period. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd during the 2nd quarter worth approximately $27,000. Finally, Marshall Wace LLP bought a new stake in shares of Invivyd during the 2nd quarter worth approximately $158,000. 70.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open‑market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (≈1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double‑digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. HC Wainwright upped their price target on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.